Acute Coronary Syndromes (ACS) News

  • Vorapaxar Meets End Point But Ups Bleeding In its second phase 3 trial, Merck's novel antiplatelet agent reduced ischemic events but increased bleeding, including ICH. Results looked more promising in patients without a history of stroke.
    Heartwire, February 7, 2012
  • CRT Bivalirudin Safe After Fondaparinux in PCI Patients Recent studies have shown that ACS patients on fondaparinux prior to PCI should switch to another anticoagulant prior to the procedure to avoid thrombus. The SWITCH III trial compares bivalirudin and unfractionated heparin in a small group of these patients.
    Heartwire, February 7, 2012
More
 

Acute Coronary Syndromes (ACS) Perspectives

More
 

Acute Coronary Syndromes (ACS) Journal Articles

More
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC. This website also contains material copyrighted by 3rd parties.